- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04711850
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection Episode
Study Overview
Detailed Description
AMR is one of the most challenging adverse events following kidney transplantation and a major cause of graft dysfunction and graft loss. AMR is triggered by donor-specific antibodies (DSA).Transplant glomerulopathy is a known consequence of persistent DSA positivity which results in graft failure and return to dialysis with attendant consequences for the patient and financial costs for the health care system.
The time from transplantation to onset of clinical symptoms of AMR varies largely between individuals. An early AMR (<30 days post-transplant) is commonly classified as active AMR and most often triggered by an immunological recall response with pre-existing DSA. A late AMR (>30 days post-transplant) is classified as either active or chronic active AMR and is caused by either a recall DSA response or newly developing naïve immune response associated with de novo DSA production.
There is no currently approved therapy for AMR and patients are often treated with a combination of therapies i.e., high dose IVIg +/- rituximab, PE with low dose IVIg +/- rituximab, and eculizumab which makes analysis of efficacy of any single agent difficult. Hence, there is a large unmet clinical need for new therapies to treat AMR.
Imlifidase is an IgG-degrading enzyme of Streptococcus pyogenes that cleaves all four human subclasses of IgG with high efficacy and specificity. The rapidity of the IgG cleavage by imlifidase is considered a major advantage as compared with PE, which often requires several rounds over several days to achieve a sufficient DSA reduction. Within a few hours after imlifidase dosing, the entire pool of IgG is completely cleaved and thereby a window where IgG levels are kept very low for approximately one week is created.
The short-term efficacy and safety of imlifidase in active and chronic active AMR is being investigated in a randomized, open-label, multi-centre trial, using PE as an active control (i.e. the feeder study: 16-HMedIdeS-12). A total of 30 subjects will be included in this study (20 in the imlifidase arm and 10 in the plasma exchange arm). The primary objective is to investigate the efficacy of imlifidase in removing DSA in patients who are experiencing an AMR episode after kidney transplantation.
While a rapid removal of DSA by imlifidase might be expected, DSA is likely to rebound unless well-controlled by concomitant immunosuppressive therapy. Therefore, there is also a need to address the long-term outcome of imlifidase as an AMR therapy. This will be studied during an extended follow-up period of 3 years in this study. Data for parameters such as kidney graft survival, patient survival, kidney function, treatment of rebound of donor specific antibodies (DSA) and anti-drug antibodies (ADAs) will be collected.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Central Contact
- Phone Number: +46 (0)46 16 56 70
- Email: clinicalstudyinfo@hansabiopharma.com
Study Locations
-
-
-
Vienna, Austria, 1090
- Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW
-
-
-
-
-
Bordeaux, France, 33076
- Hôpital Pellegrin
-
Grenoble, France, 38043
- CHU Grenoble Alpes - Néphrologie, dialyse et transplantation
-
Paris, France, 75475
- Hôpital Saint-Louis. Service de Néphrologie et Transplantation
-
Paris, France, 75742
- Hôpital Necker - Service de Néphrologie - Transplantation
-
-
-
-
-
Hannover, Germany
- Medizinische Hochschule Hannover
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed Informed Consent obtained before any trial-related procedures
- Willingness and ability to comply with the protocol
- Previous treatment with imlifidase or plasma exchange in the trial 16-HMedIdeS-12
Note: The primary objective of this trial is overall graft survival after treatment with imlifidase or plasma exchange. Therefore, subjects can also be included even if the subject did not fully complete the feeder trial follow up but was dosed with imlifidase or plasma exchange in the trial 16-HMedIdeS-12.
Exclusion Criteria:
• Inability by the judgement of the investigator to participate in the trial for any other reason
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Imlifidase treatment in feeder Study 16-HMedIdeS-12
No treatment is given in this long-term follow-up study.
In the feeder study (16-HMedIdeS-12) the patients in this group were treated with imlifidase.
|
Immunoglobulin G degrading enzyme of Streptococcus pyogenes
Other Names:
|
Plasma exchange (PE) treatment in feeder Study 16-HMedIdeS-12
No treatment is given in this long-term follow-up study.
In the feeder study (16-HMedIdeS-12) the patients in this group were treated with PE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall graft survival at Year 3
Time Frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Graft survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to graft loss.
Graft loss is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy.
|
3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall graft survival at Year 1 and Year 2
Time Frame: 1 and 2 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Graft survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to graft loss.
Graft loss is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy.
|
1 and 2 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Patient survival at Year 3
Time Frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Overall patient survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to death for any cause.
|
3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Kidney function as evaluated by eGFR
Time Frame: 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Estimated glomerular filtration rate (eGFR) was calculated as described by the Modification of Diet in Renal Disease Study (MDRD) equation.
eGFR is a measure of kidney function.
eGFR for a kidney with normal function is 90 mL/min/1.72m2.
Kidney disease is characterised by a decreased eGFR value.
|
1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Kidney function as evaluated by S/P-creatinine
Time Frame: 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
S/P-creatinine is a measure of kidney function.
Kidney disease is characterized by an increased S/P-creatinine level.
|
1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Kidney function as evaluated by albumin/creatinine ratio (ACR) in urine
Time Frame: 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
ACR in urine is a measure of kidney function.
Kidney disease is characterized by an increased ACR in urine.
|
1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Presumed or Biopsy proven AMR episodes
Time Frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Information about rejection episodes will be collected, according to Banff 2017 or later classification.
For-cause biopsies together with contemporaneous local DSA analyses, kidney function parameters (creatinine, albumin/creatinine ratio in urine) and treatments (e.g.
plasma exchange and IVIg) will be collected to assess the rejection episodes.
|
3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Presumed or Biopsy-proven rejection episodes, (other than AMR episodes)
Time Frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Information about rejection episodes will be collected, according to Banff 2017 or later classification.
For-cause biopsies together with contemporaneous local DSA analyses, kidney function parameters (creatinine, albumin/creatinine ratio in urine) and treatments (e.g.
plasma exchange and IVIg) will be collected to assess the rejection episodes.
|
3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
DSA levels
Time Frame: 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
DSA levels will be measured using single antigen bead human leukocyte antigen (SAB-HLA) assay
|
1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
ADA levels
Time Frame: 1,2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
The immunogenicity of imlifidase will be assessed by measuring ADA levels.
|
1,2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Operations, Hansa Biopharma AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20-HMedIdes-18
- 2020-004777-49 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant Rejection
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
Rush University Medical CenterCareDxCompletedKidney Transplant Rejection | Pancreas Transplant RejectionUnited States
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
Ajay IsraniNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingKidney Transplant Rejection | Kidney TransplantUnited States
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Viela Bio (acquired by Horizon Therapeutics)CompletedKidney Transplantation | Transplant Rejection | Allografts | Rejection; Transplant, KidneyUnited States
-
Columbia UniversityVeloxis PharmaceuticalsActive, not recruitingRenal Transplant Rejection | Kidney Transplant Failure and RejectionUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
Western Sydney Local Health DistrictNot yet recruitingKidney Transplant Rejection | Transplant Complication
Clinical Trials on Imlifidase
-
Hansa Biopharma ABCompletedKidney Transplant Failure and RejectionUnited States, Sweden, France
-
Hansa Biopharma ABActive, not recruitingKidney Transplantation in Highly Sensitized PatientsUnited States
-
Cedars-Sinai Medical CenterHansa Biopharma ABCompleted
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsSpain, Finland, Sweden
-
Hansa Biopharma ABCompletedKidney Transplant RejectionAustralia, United States, Germany, France, Austria
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsSpain, Italy, France, Netherlands, Belgium, Austria, Czechia, Sweden, United Kingdom, Slovenia
-
Sarepta Therapeutics, Inc.Hansa Biopharma ABActive, not recruitingDuchenne Muscular DystrophySpain
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsUnited States
-
Hansa Biopharma ABRecruitingLong Term Efficacy and SafetySpain, Czechia
-
Hansa Biopharma ABCompletedGuillain-Barré Syndrome (GBS)France, Netherlands, United Kingdom